Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of iron deficiency with incident cardiovascular diseases and mortality in the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Three decades of heart transplantation: experience and long-term outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Rosa Lauppe
  • Johan Liseth Hansen
  • Anna Fornwall
  • Katarina Johansson
  • Mark H Rozenbaum
  • Anne Mette Strand
  • Merja Vakevainen
  • Johanna Kuusisto
  • Einar Gude
  • J Gustav Smith
  • Finn Gustafsson
Vis graf over relationer

AIMS: Transthyretin amyloid cardiomyopathy (ATTR-CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR-CM patients compared with heart failure (HF) patients, in Denmark, Finland, Norway, and Sweden.

METHODS AND RESULTS: Data from nationwide healthcare registers in the four countries were used. ATTR-CM patients were defined as individuals diagnosed with amyloidosis and cardiomyopathy or HF between 2008 and 2018. Patients in the ATTR-CM cohort were matched to patients with HF but without ATTR-CM diagnosis. Resource use included number of visits to specialty outpatient and inpatient hospital care. A total of 1831 ATTR-CM and 1831 HF patients were included in the analysis. The mean number of hospital-based healthcare contacts increased in both the ATTR-CM and HF cohort during 3 years pre-diagnosis and was consistently higher for the ATTR-CM cohort compared with the HF cohort, with 6.1 [CI: 5.9-6.3] vs. 3.2 [CI: 3.1-3.3] outpatient visits and 1.03 [CI: 0.96-1.1] vs. 0.7 [CI: 0.7-0.8] hospitalizations. In the first year following diagnosis, patients with ATTR-CM continued to visit outpatient care (10.2 [CI: 10.1, 10.4] vs. 5.7 [CI: 5.6, 5.9]) and were admitted to hospital more frequently (3.3 [CI: 3.2, 3.4] vs. 2.5 [CI: 2.5, 2.6]) than HF patients.

CONCLUSIONS: Transthyretin amyloid cardiomyopathy imposes a high burden on healthcare systems with twice as many outpatient specialist visits and 50% more hospitalizations in the year after diagnosis compared with HF patients without ATTR-CM. Studies to investigate if earlier diagnosis and treatment of ATTR-CM may lower resource use are warranted.

OriginalsprogEngelsk
TidsskriftESC Heart Failure
Vol/bind9
Udgave nummer3
Sider (fra-til)1636-1642
Antal sider7
ISSN2055-5822
DOI
StatusUdgivet - jun. 2022

Bibliografisk note

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

ID: 76070699